close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.

Continue
  1. Access to americanmigrainefoundation.org is not intended to provide medical advice or a referral to a particular physician;
  2. Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure;
  3. Patients should discuss the risks and benefits of any procedure with their physician;
  4. americanmigrainefoundation.org is an independent entity, and not affiliated with, or an agent of, Amgen Inc.
  5. Amgen Inc. has not entered into any agreement with any doctor affiliated with americanmigrainefoundation.org to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through, americanmigrainefoundation.org.
  6. AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) AMERICANMIGRAINEFOUNDATION.ORG. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG. BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES HARMLESS FROM ANY AND ALL CLAIMS ARISING FROM OR IN CONNECTION WITH ANY ACT OR OMISSION OF AMERICANMIGRAINEFOUNDATION.ORG.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen Inc. is not responsible for and does not endorse or control the content contained on this third-party website.

Click “OK” to proceed or “CANCEL” to return to aimovig.com

By clicking “OK” below, you acknowledge that you have read and reviewed the information contained within the Notice of Third-Party Site at the bottom of the page.

OK CANCEL

Aimovig Was Specifically Designed
to Help Prevent Migraine

It’s proven to help prevent monthly migraine days.

Find out how Aimovig works:
In your body, you have CGRP (calcitonin gene-related peptide) and CGRP receptors

Aimovig Was Specifically Designed
to Help Prevent Migraine

It’s proven to help prevent monthly migraine days.

Find out how Aimovig works:
CGRP attaches to and activates the receptor, which may play a key role in migraine

Aimovig Was Specifically Designed
to Help Prevent Migraine

It’s proven to help prevent monthly migraine days.

Find out how Aimovig works:
Aimovig blocks the CGRP receptor so CGRP cannot attach to it

Aimovig Was Specifically Designed
to Help Prevent Migraine

It’s proven to help prevent monthly migraine days.

Find out how Aimovig works:
Aimovig is the first and only preventive migraine treatment designed to block the CGRP receptor

In clinical trials, Aimovig was proven to help prevent monthly migraine days. For some, it cut that number in half or more.
~7
fewer days
on average

Chronic Migraine

In a 3-month study

People with chronic migraine* taking Aimovig experienced ~7 fewer monthly migraine days on average (vs ~4 for placebo).

50% or more reduction in monthly migraine days. About 40% of Aimovig users saw a reduction in about 7 fewer monthly migraine days

~40% of people with chronic migraine* taking Aimovig cut their monthly migraine days by 50% or more (vs ~24% for placebo).

*Chronic migraine is defined as 15 or more headache days per month, at least 8 of which were migraine days.

3-4
fewer days
on average

Episodic Migraine

In a 6-month study

People with episodic migraine† taking Aimovig experienced 3-4 fewer monthly migraine days on average (vs ~2 for placebo).

50% or more reduction in monthly migraine days. Up to 50% of Aimovig users saw a reduction in about 4 fewer monthly migraine days

Up to 50% of people with episodic migraine† taking Aimovig cut their monthly migraine days by 50% or more (vs ~27% for placebo).

†Episodic migraine is defined as 4-14 migraine days per month.

Frequently asked questions

  • Can I use Aimovig with acute or other preventive migraine medications?
    Please talk with your doctor about what other migraine medications you can take with Aimovig. Always tell your doctor and pharmacist about all the medicines you take, including prescription and over-the-counter drugs, vitamins, and herbal supplements.
  • What is the difference between acute and preventive migraine treatments?
    Acute treatments help to reduce migraine symptoms at the onset of a migraine episode. Preventive treatments are used to try and stop migraine symptoms before they start in the first place.
  • Why do doctors think that CGRP may be linked to migraine?
    CGRP levels have been shown to increase during a migraine attack and decrease with headache relief.
  • How can Aimovig help prevent migraine?
    Aimovig is proven to help prevent monthly migraine days by blocking the interaction between CGRP and the CGRP receptor.

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 
–

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation or constipation associated with symptoms such as severe or constant belly pain, vomiting, swelling of belly or bloating.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.